Newsroom

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Cloud Computing UCITS ETF 08.05.2026 CPQ IE00BFD2H405 6,825,002.00 USD 372,584,393.74 54.591  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Dow Jones Internet UCITS ETF 08.05.2026 FDNU IE00BG0SSC32 1,225,002.00 USD 45,272,456.57 36.957  ...

TOKYO--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) today revealed its next Five-Year Business Plan (FY2026 - FY2030) that outlines how the company plans to deliver more than 2.3 trillion yen in oncology revenue by 2030 and be a global top five oncology company by 2035 as part of its larger 2035 Vision to be recognized as a “trusted healthcare innovator transforming the lives of people through science and technology.” The new Five-Year Business Plan reinforces the enduring purpose of Daiichi San...

AMSTERDAM--(BUSINESS WIRE)--AM Best has maintained its stable outlook on Italy's non-life insurance segment and expects gross written premium (GWP) in the segment to continue on a steady growth trend during 2026 across all lines of business, although at a slower pace than in recent years. In its new Best’s Market Segment Report, “Market Segment Outlook: Italy Non-Life Insurance”, AM Best also states that the additional fiscal burden from the 2026 Budget Law will not place significant pressure o...

WOIPPY, France--(BUSINESS WIRE)--Regulatory News: ABL Diagnostics (Paris:ABLD)(Euronext Compartiment B – ISIN : FR001400AHX6), société spécialisée dans le diagnostic in vitro, annonce aujourd'hui ses résultats annuels pour l'exercice clos le 31 décembre 2025, arrêtés par le Conseil d'administration lors de sa réunion du 30 avril 2026. Indicateur financier Exercice 2025 Exercice 2024 Variation (%) Chiffre d'affaires 6 950 k€ 5 330 k€ + 30,4 % Résultat opérationnel 290 k€ - 490 k€ + 159,2 % Résul...

WOIPPY, France--(BUSINESS WIRE)--Regulatory News: ABL Diagnostics (Paris:ABLD)(Euronext Compartment B – ISIN: FR001400AHX6), a company specialized in in vitro diagnostics, today announces its annual results for the fiscal year ended December 31, 2025, approved by the Board of Directors during its meeting on April 30, 2026. Financial Indicator FY 2025 FY 2024 Change (%) Revenue €6,950k €5,330k +30.4% Operating Result €290k -€490k +159.2% Net Income €987k €285k +246.0% Cash-Flow from Operations €...

LITTLETON, Mass.--(BUSINESS WIRE)--Proton therapy is entering the LINAC vault. At ESTRO 2026, Mevion Medical Systems will introduce the MEVION S250-FIT Proton Therapy System to the European radiation oncology community, the first proton therapy system designed for installation in a standard radiation therapy vault. Now both U.S. FDA-cleared and CE-marked under Regulation (EU) 2017/745, the S250-FIT creates a new pathway for cancer centers to bring proton therapy into existing LINAC-based treatm...

MALAKOFF, France--(BUSINESS WIRE)--Regulatory News: This press release and the information it contains must not be distributed, directly or indirectly, in the United States, Canada, Japan or Australia. Theraclion (ISIN: FR0010120402; Ticker: ALTHE), an innovative company developing a robotic platform for non‑invasive therapy using high‑intensity focused ultrasound (HIFU) for the treatment of varicose veins (the “Company”), announces the strong success of its € 5,992,544.16 capital increase with...

MALAKOFF, France--(BUSINESS WIRE)--Regulatory News: Ce communiqué et les informations qu’il contient ne doivent pas être distribués, directement ou indirectement, aux Etats-Unis, au Canada, au Japon et en Australie. Theraclion (ISIN : FR0010120402 - Mnemo : ALTHE), société innovante développant une plateforme robotique pour la thérapie non invasive par ultrasons focalisés de haute intensité (HIFU) pour le traitement des varices (la « Société »), annonce le fort succès de l’augmentation de capit...

BARCELONA--(BUSINESS WIRE)--Almirall, S.A. (ALM), a global pharmaceutical company dedicated to medical dermatology, today announced its financial results for the first quarter of 2026. Almirall continued to deliver on the company’s growth trajectory in line with expectations and the long-term strategy, led by 19.3% YoY growth of its European Dermatology business to €166.3 MM. During Q1 2026, total Net Sales increased by 2.2% YoY to €291 MM, with growth mainly driven by the biologics and continu...